Motif Bio is a clinical-stage biopharmaceutical company focused on developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant Gram-positive bacteria, including MRSA.
Motif is confident there is a path to market for iclaprim, it will require a company with deeper pockets to take the putative treatment further.
